Aflac Reports Q4 2025 Earnings with Mixed Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy AFL?
Source: seekingalpha
Aflac Inc (AFL) shares rose by 3.00% and reached a 52-week high amid a challenging market environment, as both the Nasdaq-100 and S&P 500 indices experienced declines of 1.15% and 1.00%, respectively.
The company's Q4 2025 earnings report revealed a revenue decline of 9.9% year-over-year, totaling $4.9 billion, and a net earnings drop of 27.5% to $1.4 billion. Despite these challenges, Aflac Japan reported a significant 15.7% increase in new annualized premium sales, driven by the cancer insurance product Miraito, indicating potential for future growth. Additionally, Aflac announced a 5.2% increase in its dividend and a substantial share repurchase program, reflecting a commitment to shareholder value.
These mixed results suggest that while Aflac faces competitive pressures, its strategic focus on product innovation and capital management may bolster investor confidence in the long term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFL
Wall Street analysts forecast AFL stock price to fall
11 Analyst Rating
3 Buy
5 Hold
3 Sell
Hold
Current: 115.480
Low
100.00
Averages
110.90
High
125.00
Current: 115.480
Low
100.00
Averages
110.90
High
125.00
About AFL
Aflac Incorporated provides financial protection to policyholders and customers through its subsidiaries in the United States and Japan. The Company’s principal business is supplemental health and life insurance products. The Company’s segments include Aflac Japan, which includes Aflac Life Insurance Japan (ALIJ), and Aflac U.S., which includes American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS). The Aflac Japan segment is the insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force. The Company designs its United States insurance products to provide supplemental coverage for people who already have major medical or primary insurance coverage, as Aflac U.S. insurance policies pay benefits regardless of other insurance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aflac Misses Q1 Revenue Expectations, Faces Challenges
- Revenue Shortfall: Aflac's Q1 revenue of $4.24 billion fell 1.8% year-over-year and missed analyst expectations of $4.32 billion, indicating challenges in maintaining revenue growth that could impact investor confidence moving forward.
- Profitability Decline: The adjusted EPS of $1.75 was 2.5% below the expected $1.80, reflecting pressures on cost control and sales growth, which may lead to short-term stock price pressure as investors reassess the company's performance.
- Sales Growth in Japan: Strong sales momentum in Japan, particularly from new medical and cancer insurance products, saw a 25.5% increase; however, persistency and lapse issues prevented a corresponding rise in earned premiums, highlighting a gap between market potential and actual performance.
- Reinsurance Strategy Expansion: Aflac executed its first third-party reinsurance deal in Japan, which, while having a minor short-term financial impact, is viewed by management as a strategic platform for future growth and diversification of earnings, indicating a forward-looking approach in their strategic planning.
See More
Aflac Reports Mixed Q1 Earnings Amid Yen Weakness
- Earnings Performance: Aflac's adjusted earnings per diluted share rose 5.4% year-over-year to $1.75, although this fell short of the Visible Alpha consensus of $1.80, indicating pressure on the company's profitability.
- Exchange Rate Impact: The average yen/dollar exchange rate was 156.87, 2.8% weaker than last year's 152.40, negatively impacting adjusted EPS by $0.02, reflecting the direct effect of currency fluctuations on financial results.
- Revenue Growth: The company reported revenue of $4.35 billion for the first quarter, a 27.9% increase year-over-year, surpassing market expectations of $4.32 billion, indicating strong performance in revenue generation.
- Premium Variations: Net earned premiums in Japan decreased by 6.4% to $1.6 billion, while net earned premiums in the U.S. increased by 3.5% to $1.6 billion, highlighting performance disparities across different markets and their impact on overall results.
See More
Aflac Launches Check for Cancer Champions Program
- Cancer Screening Advocacy: Aflac launches the Check for Cancer Champions program during Cancer Prevention and Early Detection Month to raise public awareness about the importance of cancer screening, emphasizing that preventive care and early detection can save lives.
- Initial Participants: The inaugural edition will feature six individuals who have shown unwavering commitment to raising awareness about cancer screening, reflecting Aflac's social responsibility in the health insurance sector.
- Impact Expansion: Through this initiative, Aflac not only enhances its brand image but also solidifies its market position as the leading supplemental health insurance provider in the U.S., promoting increased health awareness.
- Long-term Strategic Goals: This event aligns with Aflac's broader Check for Cancer initiative, aiming to promote early detection through education and outreach, thereby reducing cancer-related mortality rates in the future.
See More
AFLAC Q1 Earnings Announcement Scheduled
- Earnings Release Date: AFLAC is set to announce its Q1 earnings on April 29 after market close, with a consensus EPS estimate of $1.80, reflecting an 8.4% year-over-year growth, indicating sustained profitability that could positively impact stock prices.
- Revenue Expectations: The anticipated revenue for Q1 is $4.33 billion, representing a 27.4% year-over-year increase, which highlights the company's strong market performance and may bolster investor confidence, potentially driving stock prices higher.
- Historical Performance: Over the past two years, AFLAC has exceeded EPS and revenue estimates 63% of the time, demonstrating stability and reliability in financial forecasting, which could attract more institutional investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen five upward and five downward revisions, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic market outlook on AFLAC's profitability and revenue growth, which may influence future stock price movements.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
Aflac Named Among 15 Best Cheap Dividend Stocks
- Target Price Adjustment: UBS has lowered Aflac's (AFL) price target from $116 to $114 while maintaining a Neutral rating, indicating limited profitability potential amid economic uncertainty and cyclicality.
- Earnings Guidance: During the Q4 2025 earnings call, Aflac executives stated that most of the 2026 guidance remains intact, with underlying earned premiums in Japan expected to decline by 1% to 2%, which could pressure overall revenue.
- US Business Outlook: Aflac anticipates net earned premium growth to remain at the lower end of the 3% to 6% range, with a projected benefit ratio between 48% and 52%, suggesting challenges as the company expands its newer business lines.
- Expense Ratio Forecast: The company expects the expense ratio in the U.S. to range from 36% to 39%, indicating ongoing efforts to optimize its business structure despite economic headwinds to support future growth.
See More
Aflac Misses Q1 Revenue Expectations, Faces Challenges
- Revenue Shortfall: Aflac's Q1 revenue of $4.24 billion fell 1.8% year-over-year and missed analyst expectations of $4.32 billion, indicating challenges in maintaining revenue growth that could impact investor confidence moving forward.
- Profitability Decline: The adjusted EPS of $1.75 was 2.5% below the expected $1.80, reflecting pressures on cost control and sales growth, which may lead to short-term stock price pressure as investors reassess the company's performance.
- Sales Growth in Japan: Strong sales momentum in Japan, particularly from new medical and cancer insurance products, saw a 25.5% increase; however, persistency and lapse issues prevented a corresponding rise in earned premiums, highlighting a gap between market potential and actual performance.
- Reinsurance Strategy Expansion: Aflac executed its first third-party reinsurance deal in Japan, which, while having a minor short-term financial impact, is viewed by management as a strategic platform for future growth and diversification of earnings, indicating a forward-looking approach in their strategic planning.
See More
Aflac Reports Mixed Q1 Earnings Amid Yen Weakness
- Earnings Performance: Aflac's adjusted earnings per diluted share rose 5.4% year-over-year to $1.75, although this fell short of the Visible Alpha consensus of $1.80, indicating pressure on the company's profitability.
- Exchange Rate Impact: The average yen/dollar exchange rate was 156.87, 2.8% weaker than last year's 152.40, negatively impacting adjusted EPS by $0.02, reflecting the direct effect of currency fluctuations on financial results.
- Revenue Growth: The company reported revenue of $4.35 billion for the first quarter, a 27.9% increase year-over-year, surpassing market expectations of $4.32 billion, indicating strong performance in revenue generation.
- Premium Variations: Net earned premiums in Japan decreased by 6.4% to $1.6 billion, while net earned premiums in the U.S. increased by 3.5% to $1.6 billion, highlighting performance disparities across different markets and their impact on overall results.
See More
Aflac Launches Check for Cancer Champions Program
- Cancer Screening Advocacy: Aflac launches the Check for Cancer Champions program during Cancer Prevention and Early Detection Month to raise public awareness about the importance of cancer screening, emphasizing that preventive care and early detection can save lives.
- Initial Participants: The inaugural edition will feature six individuals who have shown unwavering commitment to raising awareness about cancer screening, reflecting Aflac's social responsibility in the health insurance sector.
- Impact Expansion: Through this initiative, Aflac not only enhances its brand image but also solidifies its market position as the leading supplemental health insurance provider in the U.S., promoting increased health awareness.
- Long-term Strategic Goals: This event aligns with Aflac's broader Check for Cancer initiative, aiming to promote early detection through education and outreach, thereby reducing cancer-related mortality rates in the future.
See More
AFLAC Q1 Earnings Announcement Scheduled
- Earnings Release Date: AFLAC is set to announce its Q1 earnings on April 29 after market close, with a consensus EPS estimate of $1.80, reflecting an 8.4% year-over-year growth, indicating sustained profitability that could positively impact stock prices.
- Revenue Expectations: The anticipated revenue for Q1 is $4.33 billion, representing a 27.4% year-over-year increase, which highlights the company's strong market performance and may bolster investor confidence, potentially driving stock prices higher.
- Historical Performance: Over the past two years, AFLAC has exceeded EPS and revenue estimates 63% of the time, demonstrating stability and reliability in financial forecasting, which could attract more institutional investor interest.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen five upward and five downward revisions, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic market outlook on AFLAC's profitability and revenue growth, which may influence future stock price movements.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
Aflac Named Among 15 Best Cheap Dividend Stocks
- Target Price Adjustment: UBS has lowered Aflac's (AFL) price target from $116 to $114 while maintaining a Neutral rating, indicating limited profitability potential amid economic uncertainty and cyclicality.
- Earnings Guidance: During the Q4 2025 earnings call, Aflac executives stated that most of the 2026 guidance remains intact, with underlying earned premiums in Japan expected to decline by 1% to 2%, which could pressure overall revenue.
- US Business Outlook: Aflac anticipates net earned premium growth to remain at the lower end of the 3% to 6% range, with a projected benefit ratio between 48% and 52%, suggesting challenges as the company expands its newer business lines.
- Expense Ratio Forecast: The company expects the expense ratio in the U.S. to range from 36% to 39%, indicating ongoing efforts to optimize its business structure despite economic headwinds to support future growth.
See More
